Cargando…

Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1

Circular RNAs (circRNAs) represent a widespread class of non-coding RNAs generated from back-splicing, with a circular loop structure. Many circRNAs have been reported to play essential roles in cancer development and have the potential to serve as a novel class of biomarkers for clinical diagnosis....

Descripción completa

Detalles Bibliográficos
Autores principales: Kun-Peng, Zhu, Xiao-Long, Ma, Chun-Lin, Zhang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859477/
https://www.ncbi.nlm.nih.gov/pubmed/29559849
http://dx.doi.org/10.7150/ijbs.24360
_version_ 1783307830303916032
author Kun-Peng, Zhu
Xiao-Long, Ma
Chun-Lin, Zhang
author_facet Kun-Peng, Zhu
Xiao-Long, Ma
Chun-Lin, Zhang
author_sort Kun-Peng, Zhu
collection PubMed
description Circular RNAs (circRNAs) represent a widespread class of non-coding RNAs generated from back-splicing, with a circular loop structure. Many circRNAs have been reported to play essential roles in cancer development and have the potential to serve as a novel class of biomarkers for clinical diagnosis. However, the role of circRNA in osteosarcoma (OS) remains largely unknown. In the current study, we examined the expression level of circular RNA PVT1 (circPVT1), previously screened and identified the oncogenic role in gastric cancer, in OS and found that circPVT1 was significantly up-regulated in the OS tissues, serums and chemoresistant cell lines, correlated with poor prognosis of OS patients. Besides, ROC curve demonstrated that circPVT1 may be a better diagnostic biomarker than alkaline phosphatase (ALP) in OS with more sensitivity and specificity. In addition, functional assays revealed that circPVT1 knockdown by siRNA could weaken the resistance to doxorubicin and cisplatin of OS cells through decreasing the expression of classical drug resistance-related gene ABCB1. These findings may provide a new insight into the role of circPVT1 as a biomarker for the diagnosis and treatment target of OS.
format Online
Article
Text
id pubmed-5859477
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-58594772018-03-20 Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1 Kun-Peng, Zhu Xiao-Long, Ma Chun-Lin, Zhang Int J Biol Sci Research Paper Circular RNAs (circRNAs) represent a widespread class of non-coding RNAs generated from back-splicing, with a circular loop structure. Many circRNAs have been reported to play essential roles in cancer development and have the potential to serve as a novel class of biomarkers for clinical diagnosis. However, the role of circRNA in osteosarcoma (OS) remains largely unknown. In the current study, we examined the expression level of circular RNA PVT1 (circPVT1), previously screened and identified the oncogenic role in gastric cancer, in OS and found that circPVT1 was significantly up-regulated in the OS tissues, serums and chemoresistant cell lines, correlated with poor prognosis of OS patients. Besides, ROC curve demonstrated that circPVT1 may be a better diagnostic biomarker than alkaline phosphatase (ALP) in OS with more sensitivity and specificity. In addition, functional assays revealed that circPVT1 knockdown by siRNA could weaken the resistance to doxorubicin and cisplatin of OS cells through decreasing the expression of classical drug resistance-related gene ABCB1. These findings may provide a new insight into the role of circPVT1 as a biomarker for the diagnosis and treatment target of OS. Ivyspring International Publisher 2018-02-12 /pmc/articles/PMC5859477/ /pubmed/29559849 http://dx.doi.org/10.7150/ijbs.24360 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Kun-Peng, Zhu
Xiao-Long, Ma
Chun-Lin, Zhang
Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1
title Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1
title_full Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1
title_fullStr Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1
title_full_unstemmed Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1
title_short Overexpressed circPVT1, a potential new circular RNA biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating ABCB1
title_sort overexpressed circpvt1, a potential new circular rna biomarker, contributes to doxorubicin and cisplatin resistance of osteosarcoma cells by regulating abcb1
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5859477/
https://www.ncbi.nlm.nih.gov/pubmed/29559849
http://dx.doi.org/10.7150/ijbs.24360
work_keys_str_mv AT kunpengzhu overexpressedcircpvt1apotentialnewcircularrnabiomarkercontributestodoxorubicinandcisplatinresistanceofosteosarcomacellsbyregulatingabcb1
AT xiaolongma overexpressedcircpvt1apotentialnewcircularrnabiomarkercontributestodoxorubicinandcisplatinresistanceofosteosarcomacellsbyregulatingabcb1
AT chunlinzhang overexpressedcircpvt1apotentialnewcircularrnabiomarkercontributestodoxorubicinandcisplatinresistanceofosteosarcomacellsbyregulatingabcb1